Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Japan’s Ministry of Health, Labour and Welfare approved Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval is based on data from the L-MIND Phase II trial, which showed a 58.8% overall response rate, and the J-MIND Phase Ib/II trial in Japan, which showed a 71.4% response rate.
Key figures
- Drug Name
- Minjuvi (tafasitamab)
- Phase Of Trial
- Phase II
- J mind cr
- 45.2%
- L mind cr
- 41.3%
- J mind orr
- 71.4%
- L mind orr
- 58.8%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.